Palouse Capital Management Inc. Sells 115 Shares of Becton, Dickinson and Company (NYSE:BDX)

by · The Cerbat Gem

Palouse Capital Management Inc. decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 3.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,946 shares of the medical instruments supplier’s stock after selling 115 shares during the quarter. Palouse Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $710,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Wedmont Private Capital bought a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $227,000. Strong Tower Advisory Services increased its holdings in Becton, Dickinson and Company by 7.5% in the 1st quarter. Strong Tower Advisory Services now owns 4,999 shares of the medical instruments supplier’s stock worth $1,220,000 after buying an additional 349 shares in the last quarter. Jacobs & Co. CA lifted its stake in Becton, Dickinson and Company by 1.0% during the 1st quarter. Jacobs & Co. CA now owns 47,939 shares of the medical instruments supplier’s stock valued at $11,862,000 after acquiring an additional 456 shares during the period. Fermata Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 12.0% during the 1st quarter. Fermata Advisors LLC now owns 1,238 shares of the medical instruments supplier’s stock valued at $306,000 after acquiring an additional 133 shares during the last quarter. Finally, DLK Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 7.8% in the first quarter. DLK Investment Management LLC now owns 18,174 shares of the medical instruments supplier’s stock worth $4,497,000 after acquiring an additional 1,320 shares during the period. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Raymond James dropped their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Stifel Nicolaus increased their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $282.63.

Get Our Latest Research Report on Becton, Dickinson and Company

Becton, Dickinson and Company Price Performance

BDX stock traded down $3.54 during midday trading on Monday, reaching $240.21. The stock had a trading volume of 269,004 shares, compared to its average volume of 1,388,729. The company has a market cap of $69.42 billion, a price-to-earnings ratio of 53.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $262.23. The company’s fifty day simple moving average is $237.01 and its 200 day simple moving average is $235.18.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same period in the prior year, the business posted $2.96 earnings per share. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.58%. The ex-dividend date of this dividend was Monday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Recommended Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).